Christopher James Hill's Ownership Filing for Adaptimmune Therapeutics PLC

Christopher James Hill, the Chief Financial Officer of Adaptimmune Therapeutics PLC, filed a Form 3 with the SEC on October 8, 2025, reporting his ownership as of September 10, 2025. The filing indicates that Hill does not own any securities of the company. The form was signed by Hill and provides his address in Abingdon, United Kingdom. This filing is a routine disclosure required for officers and directors to report their ownership or changes in ownership of company securities.